Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP10 | P09238 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31017572 | 0.98 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL31507005 | 0.89 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL22954629 | 0.87 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9960236 | 0.86 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL18046957 | 0.83 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21380508 | 0.82 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25340995 | 0.80 | MAPK1 (0.34) | CYP1A2KDM4EKMT2A | |
| SCHEMBL2845209 | 0.80 | OPRM1 (0.41) | KMT2ACYP2C19CYP3A4 | |
| SCHEMBL17318365 | 0.80 | CHRNB2 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL29768055 | 0.80 | SMN1; SMN2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724435-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | Nurix Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250197413-A1 | RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY | 2025-06-19 | — | — | US | disclosed |
| WO-2025128938-A1 | BENZOTHIAZOLE DERIVATIVES USEFUL AS RXFP1 RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| WO-2024254532-A1 | BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-116322700-B | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-08-20 | — | — | CN | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018238-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023017446-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-02-16 | — | — | WO | disclosed |
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | BEONE MEDICINES I GMBH (CH) | 2021-09-30 | — | — | US | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2021-06-22 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2020-11-12 | — | — | US | disclosed |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-07-14 | — | — | US | disclosed |
| WO-2019228403-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2019-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300936-A1 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST | ADORA2A, ADORA3, ADORA2B | CHRNB2 808/4885CHRNA4 484/4885CHRNB4 961/4885 |
| US-20250197413-A1 | RXFP1 RECEPTOR AGONISTS | RXFP1, RXFP3, RXFP2 | CHRNB2 423/4885CHRNA4 504/4885CHRNB4 563/4885 |
| US-10711000-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | CHRNB2 3611/4885CHRNA4 4453/4885CHRNB4 3781/4885 |
| US-11040972-B2 | Autotaxin inhibitors and uses thereof | ENPP2, SERPINB1, RNASE1 | CHRNB2 3611/4885CHRNA4 4453/4885CHRNB4 3781/4885 |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CHRNB2 3731/4885CHRNA4 4344/4885CHRNB4 3979/4885 |
| US-20250051344-A1 | BIFUNCTIONAL SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF | SMARCA2, SMARCE1, SMARCB1 | CHRNB2 3382/4885CHRNA4 4656/4885CHRNB4 4317/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CHRNB2 3481/4885CHRNA4 3546/4885CHRNB4 3476/4885 |
| US-20200354357-A1 | AUTOTAXIN INHIBITORS AND USES THEREOF | ENPP2, SERPINB1, RNASE1 | CHRNB2 3611/4885CHRNA4 4453/4885CHRNB4 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.